Company research
Lantern Pharma Inc.
CIK 1763950Updated Oct 22, 2026
SecurityLTRN · NASDAQ · equity
Name history
Lantern Pharma · through Jan 14, 2019
LTRN price & chart
Loading TradingView…
NASDAQ:LTRN on TradingView ↗About the company
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, re…
In the news
No coverage from other publishers is available.
Recent filings
ARS filing
DEF 14A filing
SCHEDULE 13G/A - filed by Empery Asset Management, LP regarding Lantern Pharma Inc.
PRE 14A filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
424B5 filing
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 13,626,810Source | 30,293,264Source | 8,602,349Source | 17,420,292Source | 35,586,929Source | 7,223,067Source | 21,096,335Source | 39,734,224Source | 11,035,811Source | 25,571,792Source | 43,647,616Source | 58,836,321Source |
| Property, Plant and Equipment, NetUSD | 35,977Source | 48,931Source | 24,271Source | 39,524Source | 50,292Source | 28,022Source | 44,025Source | 50,283Source | 31,875Source | 47,440Source | 52,127Source | 48,008Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,389,486Source | 8,102,819Source | 6,660,170Source | 6,061,408Source | 12,976,565Source | 4,917,796Source | 6,377,602Source | 18,357,944Source | 4,422,838Source | 7,511,079Source | 21,937,749Source | 37,201,786Source |
| Assets, CurrentUSD | 13,461,005Source | 29,920,960Source | 8,458,919Source | 17,200,790Source | 35,291,577Source | 7,057,260Source | 20,823,376Source | 39,470,861Source | 10,803,172Source | 25,247,629Source | 43,341,325Source | 58,722,737Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,098,429Source | 1,867,195Source | 1,097,664Source | 1,299,016Source | 2,029,458Source | 734,407Source | 1,101,725Source | 1,113,007Source | 683,948Source | 1,234,566Source | 2,038,653Source | 2,985,472Source |
| Operating Lease, Right-of-Use AssetUSD | 93,090Source | 286,635Source | 38,242Source | 143,240Source | 213,045Source | 56,868Source | 192,196Source | 187,211Source | 75,595Source | 239,985Source | 228,295Source | 47,687Source |
| Other Assets, NoncurrentUSD | 36,738Source | 36,738Source | 26,090Source | 36,738Source | 32,015Source | 26,090Source | 36,738Source | 25,869Source | 36,738Source | 36,738Source | 25,869Source | 17,889Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,039,972Source | 3,695,043Source | 11,819,601Source | 4,897,887Source | 4,655,492Source | 3,777,366Source | 4,319,850Source | 3,969,007Source | 4,501,587Source | 4,384,018Source | 2,739,682Source | 2,798,297Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,104Source | 1,078Source | 1,276Source | 1,078Source | 1,076Source | 1,125Source | 1,078Source | 1,076Source | 1,125Source | 1,078Source | 1,072Source | 1,086Source |
| Additional Paid in CapitalUSD | 98,616,239Source | 96,772,824Source | 100,367,581Source | 97,366,699Source | 96,581,666Source | 99,954,439Source | 97,206,073Source | 96,447,495Source | 99,652,724Source | 97,058,323Source | 96,258,726Source | 95,691,194Source |
| Retained Earnings (Accumulated Deficit)USD | -89,070,838Source | -70,150,417Source | -103,546,350Source | -84,893,415Source | -65,644,720Source | -96,474,226Source | -80,562,400Source | -60,685,214Source | -93,145,055Source | -76,025,617Source | -55,244,404Source | -39,282,870Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 40,333Source | -25,264Source | -39,759Source | 48,043Source | -6,585Source | -35,637Source | 131,734Source | 1,860Source | 25,430Source | 153,990Source | -107,460Source | -371,386Source |
| Stockholders' Equity Attributable to ParentUSD | 9,586,838Source | 26,598,221Source | -3,217,252Source | 12,522,405Source | 30,931,437Source | 3,445,701Source | 16,776,485Source | 35,765,217Source | 6,534,224Source | 21,187,774Source | 40,907,934Source | 56,038,024Source |
| Liabilities and EquityUSD | 13,626,810Source | 30,293,264Source | 8,602,349Source | 17,420,292Source | 35,586,929Source | 7,223,067Source | 21,096,335Source | 39,734,224Source | 11,035,811Source | 25,571,792Source | 43,647,616Source | 58,836,321Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,039,972Source | 3,601,090Source | 4,322,512Source | 4,884,363Source | 4,600,798Source | 3,777,366Source | 4,286,434Source | 3,953,446Source | 4,501,587Source | 4,331,175Source | 2,678,186Source | 2,798,297Source |
| Operating Lease, Liability, CurrentUSD | 93,954Source | 197,291Source | 39,715Source | 131,515Source | 164,002Source | 59,076Source | 59,076Source | 178,023Source | 78,539Source | 190,814Source | 172,975Source | 52,890Source |
| Operating Lease, Liability, NoncurrentUSD | — | 93,953Source | — | 13,524Source | 54,694Source | — | 33,416Source | 15,561Source | — | 52,843Source | 61,496Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,853Source | 4,574Source | 17,280Source | 17,282Source | 14,615Source | 10,081Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 143,685Source | 179,166Source | — | — | — | 147,750Source | 651,000Source | 652,000Source | 1,067,515Source | 1,187,745Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,772,627Source | -4,375,610Source | -15,676,980Source | -17,813,201Source | -14,346,548Source | -12,767,492Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 4,250,000Source | 3,239,331Source | 11,057,073Source | 3,369,368Source | -930,210Source | 179,268Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 1,159Source | 1,715Source | 12,595Source | 18,734Source | 27,844Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 499,997Source | 2,482,286Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 1,498,240Source | 66,710Source | -499,997Source | -2,182,498Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 494,958Source | -1,133,477Source | -3,088,241Source | -14,426,670Source | -15,805,217Source | -14,781,329Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 61,318Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | 10,368Source | 22,408Source | 9,065Source | -115,840Source | -128,922Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 77,286Source | 17,278Source | 157,965Source | -219,729Source | -11,500Source | -58,598Source |
| General and Administrative ExpenseUSD | — | — | 1,912,829Source | 1,462,930Source | 1,717,231Source | 1,583,521Source | 1,680,375Source | 1,510,077Source | 6,464,371Source | 6,090,747Source | 5,983,255Source | 5,829,799Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,177,423Source | -4,505,697Source | -7,072,124Source | -4,331,015Source | -3,329,171Source | -4,536,783Source | -17,119,438Source | -20,781,213Source | -15,961,534Source | -14,259,946Source |
| Operating ExpensesUSD | — | — | 4,349,800Source | 5,179,576Source | 3,508,090Source | 4,651,900Source | 3,405,247Source | 4,774,032Source | 17,978,494Source | 22,216,437Source | 17,877,570Source | 14,432,753Source |
| Other Nonoperating Income (Expense)USD | — | — | 71,456Source | 482,527Source | 14,926Source | 206,140Source | 33,916Source | 87,459Source | 421,125Source | 692,869Source | 1,150,648Source | -31,548Source |
| Proceeds from Issuance of Common StockUSD | — | — | 30,722Source | — | — | — | — | — | 1,624,547Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 13,442Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | -59,451Source | 151,264Source | 305,887Source | 155,624Source | 119,650Source | -492,501Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -4,349,800Source | -5,179,576Source | -3,508,090Source | -4,651,900Source | -3,405,247Source | -4,774,032Source | -17,978,494Source | -22,216,437Source | -17,877,570Source | -14,432,753Source |
| Other Nonoperating Income (Expense)USD | — | — | 71,456Source | 482,527Source | 14,926Source | 206,140Source | 33,916Source | 87,459Source | 421,125Source | 692,869Source | 1,150,648Source | -31,548Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,177,423Source | -4,505,697Source | -7,072,124Source | -4,331,015Source | -3,329,171Source | -4,536,783Source | -17,119,438Source | -20,781,213Source | -15,961,534Source | -14,259,946Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.39Source | -0.42Source | -0.57Source | -0.4Source | -0.3Source | -0.42Source | -1.57Source | -1.93Source | -1.47Source | -1.31Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.39Source | -0.42Source | -0.57Source | -0.4Source | -0.3Source | -0.42Source | -1.57Source | -1.93Source | -1.47Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 10,833,393Source | 10,763,351Source | 12,423,174Source | 10,784,725Source | 11,253,030Source | 10,784,725Source | 10,898,175Source | 10,762,319Source | 10,842,365Source | 10,850,579Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,833,393Source | 10,763,351Source | 12,423,174Source | 10,784,725Source | 11,253,030Source | 10,784,725Source | 10,898,175Source | 10,762,319Source | 10,842,365Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 3,853Source | 4,574Source | 17,280Source | 17,282Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 77,286Source | 17,278Source | 157,965Source | -219,729Source | -11,500Source | -58,598Source |
| General and Administrative ExpenseUSD | — | — | 1,912,829Source | 1,462,930Source | 1,717,231Source | 1,583,521Source | 1,680,375Source | 1,510,077Source | 6,464,371Source | 6,090,747Source | 5,983,255Source | 5,829,799Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 16,980,000Source | — | — | — |
| Interest Income, OtherUSD | — | — | 100,921Source | 191,352Source | 30,079Source | 114,745Source | 42,160Source | 149,790Source | 437,931Source | 742,355Source | 765,388Source | 204,355Source |
| Operating ExpensesUSD | — | — | 4,349,800Source | 5,179,576Source | 3,508,090Source | 4,651,900Source | 3,405,247Source | 4,774,032Source | 17,978,494Source | 22,216,437Source | 17,877,570Source | 14,432,753Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 144,000Source |
| Research and Development ExpenseUSD | — | — | 2,436,971Source | 3,716,646Source | 1,790,859Source | 3,068,379Source | 1,724,872Source | 3,263,955Source | 11,514,123Source | 16,125,690Source | 11,894,315Source | 8,602,954Source |
Offerings
Registration 333-296752
Filing attachments
ex4-1.htm · 8-K · 2026-09-30
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT Lantern Pharma Inc. Warrant Shares: _______ Initial Exercise Date: September 30, 2026 ────────────────────────────────────────────────────────────────── THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, _____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f…
Read attachment ↗ex4-2.htm · 8-K · 2026-09-30
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex4-3.htm · 8-K · 2026-09-30
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-30
Exhibit 99.1 Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants DALLAS, TEXAS - (BUSINESS WIRE) - September 29, 2026 - Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced…
Read attachment ↗ex99-2.htm · 8-K · 2026-09-30
Exhibit 99.2 Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants DALLAS, TEXAS - (BUSINESS WIRE) - September 30, 2026 - Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, toda…
Read attachment ↗